SYNAPS Dx Presents at ISPOR Annual Conference, Demonstrates 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease

SYNAPS Dx Presents at ISPOR Annual Conference, Demonstrates 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease

SYNAPS Dx announces it will present “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” at the ISPOR Annual Conference. The implicit preference study indicates that 90% of physicians would routinely use the results of DISCERN™, a diagnostic test that assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD as well as regulators of amyloid plaque and tau formation, hallmarks of AD at autopsy. ...  Read more

Channel Program to Host Channel All-Stars: A Virtual Event featuring Gary Vaynerchuk (GaryVee) and 3 All-Star Panels

Channel Program to Host Channel All-Stars: A Virtual Event featuring Gary Vaynerchuk (GaryVee) and 3 All-Star Panels

Channel Program, a rapidly growing social and media platform that is unifying the IT Channel industry, announced it is hosting what is anticipated to be the largest virtual event of the year on June 8, 2022, at 11:30 AM EDT. ...  Read more

DMV SOLUTIONS, LLC WINS GSA’S 8(A) STARS III

DMV SOLUTIONS, LLC WINS GSA’S 8(A) STARS III

DMV Solutions, LLC wins GSA’s 8(a) STARS III, a multi-award Indefinite Delivery Indefinite Quantity (IDIQ) contract #47QTCB22D0060 to provide information technology (IT) services and solutions for the 8(a) Streamlined Technology Acquisition Resource for Services (STARS) III Government-wide Acquisition Contract (GWAC). This fourth-generation contract offers IT services ranging from simple to complex and services-based solutions such as IT help-desk support, information assurance, cybersecurity, artificial intelligence (AI), robotic process automation (RPA), with two focused scope sub-areas: emerging technologies and outside continental United States (OCONUS) support. STARS III partners with the Small Business Administration (SBA) to support the development of small firms and provide federal agencies with methods to deliver mission-critical IT services while working with small businesses. ...  Read more

Growing and Launching Women-Owned Businesses

Growing and Launching Women-Owned Businesses

Maryland Women’s Business Center (MWBC) works with entrepreneurs across Maryland’s capital region by way of three locations. Through our resources, we encourage women to start, sustain, and grow their businesses. Through workshops, individual counseling, facilitated peer group support, special resources, and access to capital, MWBC annually helps more than 1,500 women gain the skills, connections, and confidence necessary to navigate entrepreneurship. ...  Read more

Two Six Technologies Acquires McLean-based Thresher

Two Six Technologies Acquires McLean-based Thresher

Arlington, Va. – Two Six Technologies, an Arlington-based provider of technology to governments, announced that it has acquired McLean-based Thresher Ventures, a developer of software that detects and analyzes media manipulation by foreign governments. Financial terms of the deal were not disclosed. Thresher’s main product – called M3 (Media Manipulation Monitor) – uses AI, natural language processing and data science to help clients understand manipulation of news and information by foreign governments. “We are thrilled to join the Two Six team and leverage our combined platform to help our clients more quickly and effectively confront the growing threats of misinformation and media manipulation around the world,” said Becky Fair, the CEO and co-founder of Thresher. ...  Read more

Rockville’s Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

Rockville’s Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults. ...  Read more

Vita Therapeutics Relocates to University of Maryland BioPark

Vita Therapeutics Relocates to University of Maryland BioPark

From its new headquarters and lab space, the biotech company aims to generate state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers

BALTIMORE, May 2, 2022 /PRNewswire/ — The University of Maryland (UM) BioPark announced today that Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies to treat muscular dystrophies and solid tumors, has established offices and laboratory space within approximately 10,000 square feet of leased space in the BioPark. Vita Therapeutics will leverage the new space to bring together its 25+-person team under one roof for the first time with the goal of progressing its co-lead programs, VTA-100 and VTA-300. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. ...  Read more

Seraxis Growth Leads to Expansion and a Complex Move to New Facilities

Seraxis Growth Leads to Expansion and a Complex Move to New Facilities

After more than a year of searching and planning, Seraxis found a new home in Montgomery County. With the assistance of experienced life sciences logistics company BaneBio, Seraxis was able to seamlessly move into its new facility earlier this year without interrupting its plans to scale and guide its lead cell therapy into the clinic. ...  Read more